



Gut Check: Exploring the Diet-Microbiome Axis and its Impact on Immunotherapy Outcomes

Carrie Daniel-MacDougall, PhD, MPH

Associate Professor, Department of Epidemiology

Director, Bionutrition Research Core

Resource Leader, Center for Energy Balance in Cancer Prevention and Survivorship

Nutrition and Epidemiology lead, Platform for Innovative Microbiome and Translational Research

No COI/disclosures

THE UNIVERSITY OF TEXAS

MD Anderson
Cancer Center

Making Cancer History®

Patient: "What should I eat?"

Microscopic view of red, rod-shaped bacteria.

5
WAYS

(THE RIGHT) BACTERIA
Can Cure Your Condition


Dr. Axe
FOOD IS MEDICINE

A bottle of vinegar and fresh vegetables.


The
Cancer
Cure Diet

The Complete
Cookbook of 20
Cancer Diet Recipes
That Work And Why


Cancer patients independently exploring different dietary strategies




- No secret formula or evidence-based dietary guidelines for cancer patients.
- Lack of dietary data collection in trials and clinical cohorts
- Lack of prospective / interventional dietary studies demonstrating change in response
- The best we can do is extrapolate from evidence-based cancer *prevention* guidelines (AICR, ACS)



Dietary patterns linked to cancer survival in prospective studies




Central index or pattern (Cancer prevention diet guidelines) represents what is common to all. Exterior connected circles show unique emphasis (+) or exclusions (-) of each diet. **Restrictive diets** (e.g., vegan vs. ketogenic) restrict or exclude certain types of foods or sources of nutrients but are otherwise flexible regarding food choices to meet those goals.



Research framework for moving from observational studies with extended outcomes to specific preclinical and clinical studies assessing the biologic effects and underlying mechanisms linking diet to cancer survival.


“Modifiable factors” in cancer patients

- Goal is effective and durable treatment response to extend survival
- Treatments constantly evolving and changing
- Obesity and poor diet are well established in cancer risk and increasingly recognized in cancer progression and outcomes
- The link between the gut microbiome and therapeutic response (or resistance) is shaping new research priorities for patients with cancer
- Patient attributes/habits may synergize with or inhibit treatment tolerance and efficacy





Gut microbiome as biomarker and target to enhance ICB response

The gut microbiome is associated with response to ICB



2L PD1 + FMT induced response in 20-30% of PD1-resistant melanoma



A range of factors are known to modulate the microbiome

Medications

(antibiotics, probiotics, proton-pump inhibitors, metformin, anti-depressants)


Diet

(fibre-rich, plant-based diet vs typical western diet)

External factors (modifiable)

Host factors (non-modifiable)

Demographics
(age, sex)



Host genomics
(genetic polymorphisms [HLA, genes affecting innate immune function])


Anthropometrics
(BMI)

Environment
(Geography, cultural preferences, environmental exposures)

Psychological factors
(depression, stress, etc)

Figure in “Modulating the microbiome to improve therapeutic response in cancer,” *Lancet Onc* 2019

It begins with food and ends with... 🍌



Prebiotics

Non-digestible fiber compounds that stimulate the growth and activity of beneficial gut microorganisms.



Probiotics

Live microorganisms that inhabit the microbiome and confer health benefits when consumed in sufficient amounts.



Synbiotics


A combination of prebiotics and probiotics.



Postbiotics

Products of prebiotic and probiotic activity that mimic some of the same benefits as probiotics, but also offer additional health benefits.

Mechanisms of immune modulation by the gut microbiota



The gut microbiota may affect immune cells playing key roles in antitumoral immunity via:

- activation of pathogen recognition receptors
- molecular mimicry initiating immune responses against cancer antigens that are similar to bacterial ones
- **metabolic modulation using vitamins, short-chain fatty acids, bile salt, or amino acids that promote favorable intracellular processes among host cells**




Team Science

- Collaborative efforts across research and clinical teams → develop strategies to target the microbiome in cancer patients with the overall goal to improve treatment response rates, reduce toxicity and extend survival.
- Over the past 5+ years, we built patient cohorts and clinical trials in melanoma (and expanded this experience to other cancers) integrating measures of various host factors not captured in the EMR
 - Diet, physical activity and other aspects of lifestyle
 - Antibiotic use
 - Supplement use
 - Patient-reported outcomes
- Parallel mechanistic studies


Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients




Jennifer Wargo





Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response



Evaluate response-associated taxa identified in our prior report (Gopalakrishnan *et al. Science* 2018) among a newly-acquired cohort of 132 patients treated with anti-PD1 (excluding patients from prior report).




Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response



Multivariable-adjusted (subtype, stage, LDH, BMI) HR and 95% CI per 5 g/day increase:

0.71 (0.52, 0.98)





Fiber + no probiotics vs. else
0.44 (0.21, 0.92)

Dietary habits in stage IV melanoma survivor cohort: a population at-risk

Patients responded to queries asking about food consumption over the past month

Nutrient or Food group	Min	Mean	Max	Recommendation
Fiber	12	18	36	Below (25-30 g daily)
Calcium	768	1035	1399	Below (1000-1200 mg daily)
Whole grains	0.3	0.8	1.7	Below (3-5 servings daily)
Added Sugar	10	17	37	Above (limit 9 tsp daily)
Dairy	1.0	1.6	2.8	Below (3 servings daily)
Total fruit, veg + legumes	1.6	2.9	6.6	Below (5 servings daily)
Vegetables + legumes	1.1	1.9	4.1	Below (3 servings daily)
Fruit	0.4	1.0	4.0	Below (2 servings daily)



- >70% fell within criteria of “insufficient dietary fiber intake” associated with NR and shortened PFS (*Science* 2021)
- Overall, distributions were similar to those observed among patients in active treatment with fruit, vegetables, legumes, and whole grains contributing similarly to dietary fiber intake.
- 67% reported following a special diet
- Further investigation into the role of long-term side effects and microbiome profiles





Jennifer McQuade

Considerations and challenges ahead to modulate a patient's microbiome

	Advantages	Disadvantages	Considerations
Faecal microbiota transplant	Transplantation of entire ecosystem; direct	Scalability (difficult to access and expensive); procedural risks; potential to transfer other diseases	Donor selection (complete responder to faecal microbiota transplant vs healthy donor); delivery mechanism; need for conditioning regimen; how to sustain; banking for potential future autologous transplant
Probiotics and bacterial consortia	Easy to use; affordable; accessible	Variable engraftment in setting of competing commensals; potential for lowering overall microbiome diversity; varying bioavailability; insufficient regulations on quality control	Use of spores vs live bacteria; which bacteria to include; personalisation; need for conditioning regimen
Prebiotics (eg, fibre supplements)	Easy to use; affordable; accessible	Whole food might be more important than isolated nutrient supplements (regulated as food rather than drugs)	Single fibre vs mixture; predictability of response given resident bacterial community
Diet	Holistic change that might have other health benefits	Low compliance; difficult to sustain; varied effects	Whether to target specific nutrients vs overall pattern; dose needed for target modulation; duration needed; predictability of modulation given host variation in microbiome and metabolism


Clinical benefit of immunotherapy (response) balanced by inflammatory toxicities (irAE): microbiome central in both



Figures in “Understanding and treating the inflammatory adverse events of cancer immunotherapy,” *Cell* 2021

Diet, metabolites, and intestinal mucus link the gut microbiome to fever after cytotoxic cancer treatment

Mucin-degrading intestinal bacteria associated with development of fever after onset of post-HCT neutropenia.




Robert Jenq

Preclinical:

- Radiation or chemotherapy changes the composition of intestinal bacteria, leading to increases in *Akkermansia* and thinning of the (protective) colonic mucus layer
- Restriction of energy (calories) is sufficient to produce changes in the composition of the intestinal bacteria similar to those seen after cytotoxic therapy

Clinical: Further investigation of patients' diets and microbiota-supporting nutrients

A phased approach to dietary intervention studies



End-Goal:
Diet interventions and/or rationally designed pre/pro/syn-biotics to improve disease outcomes

DIET 1.0: Fully controlled high-fiber feeding study in n=10 melanoma survivors

- Demonstrated feasibility
- High compliance with consuming diet and providing fecal and blood specimens
- Tolerable
- Shift in microbiome and circulating metabolites

EnDVR (PreFED) trial in MD Anderson employees

- Randomized to PreFED (snacks and meal counseling) vs HFDD
- >90% snack compliance and exceeded the target of +4 prebiotic food servings
- PreFED is an equally effective regimen as HFDD to stimulate key features associated with ICI response


DIET 2.0: Controlled high-fiber feeding study melanoma patients starting SOC immunotherapy

- Enrollment completed
- Correlative studies are on going

BE GONE trial in overweight and obese colon cancer survivors

- Targeted food provision + RD counseling approach
- Tolerable
- Increases diversity (inverse Simpson index) and candidate taxa
- Anti-inflammatory metabolites and proteomic markers

Modulating a prebiotic food source (beans) influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial






Colorectal cancer survivors:

- Surveillance colonoscopy and GI Med Onc follow-up patients with issues jointly managing gut and metabolic health (obese)
- Half on statins and/or metformin
- Adequate bowel length and “normalized” bowel habits



Findings:

- 87% completed the 16-week trial; carefully monitored side effects
- ↑ diversity and shifts in multiple bacteria indicative of prebiotic efficacy, including ↑ *Faecalibacterium*, *Eubacterium* and *Bifidobacterium*
- Circulating metabolome showed parallel shifts in nutrient and microbiome-derived metabolites that regressed upon returning to the usual diet
- Shifts in proteomic biomarkers of intestinal and systemic inflammatory response

DIET 1.0: high fiber feeding study in melanoma survivors



DIET 1.0: post-study reversion to usual diet and reversion of metabolites



DIET 2.0

Metastatic melanoma patients receiving SOC ICIs

Cohort 1: Adjuvant (n=21)
 • Resected Stage II/IV melanoma with planned initiation of adjuvant ICI


Cohort 2: Unresectable (n=12)
 • Unresectable stage III or Stage IV melanoma with planned initiation of ICI

Cohort 3: Neoadjuvant (n=12)
 • Resectable melanoma with planned initiation of neoadjuvant ICI


RCC patients receiving SOC ICIs

Cohort 4: Unresectable RCC (n=12)
 • Metastatic clear-cell RCC with planned initiation of ICI


Dietary Intervention



- Primary Endpoint:**
- Establish the effects of diet intervention on structure and function of the gut microbiome
- Secondary Endpoints:**
- Systemic and tumor immunity
 - Gut metabolic output and systemic metabolism
 - Adherence
 - Quality of Life
 - Safety
 - Determine fiber content 70% of participants are able to tolerate
 - ORR, PFS, RFS




DIET 2.0



Recently completed: PLEASE DO NOT SHARE OR POST


DIET 2.0: Time on study and reason for treatment discontinuation



Recently completed: PLEASE DO NOT SHARE OR POST

DIET 2.0 compliance

Dietary fiber ramp-up from 30g to 50g via whole foods in HFDI arm



** Data incomplete in 6 patients

Recently completed: PLEASE DO NOT SHARE OR POST

DIET 2.0: adverse events in melanoma patients

Type of AEs	Healthy Diet (n=15)			HFDI (n=29)		
	Grade 1	Grade 2	Total for all grade	Grade 1	Grade 2	Total for all grade
Any diet-related AE	5 (33%)	2 (13%)	7 (47%)	9 (31%)	6 (21%)	15 (52%)
	PD1 mono 4 Ipi/Nivo 1	PD1 mono 1 Ipi/Nivo 1	PD1 mono 5 Ipi/Nivo 2	PD1 mono 4 Ipi/Nivo 4 Nivo/Rela 1	PD1 mono 4 Ipi/Nivo 2	PD1 mono 8 Ipi/Nivo 6 Nivo/Rela 1
Abdominal pain	2 (13%)	1 (7%)	3 (20%)	2 (7%)	1 (3%)	3 (20%)
Anorexia				2 (7%)		2 (7%)
Bloating	1 (7%)		1 (7%)	2 (7%)	1 (3%)	3 (10%)
Constipation	5 (33%)		5 (33%)	3 (10%)		3 (10%)
Diarrhea	2 (13%)	1 (7%)	3 (20%)	4 (14%)	3 (20%)	7 (24%)
Flatulence	2 (13%)		2 (13%)	5 (17%)	2 (7%)	7 (24%)
Hyperglycemia					1 (3%)	1 (3%)
Nausea				1 (3%)		1 (3%)
Weight Loss				4 (14%)		4 (14%)

Recently completed: PLEASE DO NOT SHARE OR POST

DIET 2.0: adverse events in melanoma patients

Type of AEs	Healthy Diet (n=15)			HFDI (n=29)		
	Grade 3	Grade 4	Total for grade III/IV	Grade 3	Grade 4	Total for grade III/IV
irAE	3 (20%)		3 (20%)	8 (28%)	1 (3%)	9 (31%)
	PD1 mono 2		PD1 mono 2	PD1 mono 4	Nivo/Rela 1	PD1 mono 4
	Ipi/Nivo 1		Ipi/Nivo 1	Ipi/Nivo 4		Ipi/Nivo 4
						Nivo/Rela 1
Autoimmune encephalitis	1 (7%)		1 (7%)			
Arthralgia				1 (3%)		1 (3%)
Bell's palsy				1 (3%)		1 (3%)
Colitis	1 (7%)		1 (7%)	2 (7%)		2 (7%)
Dyspnea				1 (3%)		1 (3%)
Fatigue				3 (10%)		3 (10%)
Immune-related hepatitis				1 (3%)		1 (3%)
Neutrophil count decreased					1 (3%)	1 (3%)
Optic neuritis	1 (7%)		1 (7%)			
Peripheral sensory neuropathy				1 (3%)		1 (3%)
Rash maculo-papular/Pruritus				1 (3%)		1 (3%)
Serum amylase increased				1 (3%)		1 (3%)
Type I diabetes	1 (7%)		1 (7%)			

Rate of Grade III/IV irAEs:
Ipi/Nivo treated= 33%
Nivo/Rela= 14%
PD1 mono = 27%

Microbiome-targeting dietary intervention trials in melanoma ICB



Jennifer McQuade

- **Diet 2.0 NCT04645680 Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, completed**



- PreFED NCT06250335 Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients, recruiting
 - + Unresectable metastatic, newly funded by NCI
 - + Neoadjuvant, newly funded by American Cancer Society
- To progress to a large, multisite trial, we need an effective, scalable strategy that can be delivered as part of the usual care and management plan, similar to prescriptive dietary regimens in other clinical settings that can be personalized and adapted to manage the underlying inflammatory process and symptom burden in parallel with drug therapies

PreFED

	Snack Menu	Prebiotic Food Servings
Day 1	Sweet potato chips, roasted garlic hummus	2.9
Day 2	Black bean brownie, raspberry chia seed jam	2.7
Day 3	Banana muffin, succotash	3.1
Day 4	Granola, sauteed brussel sprouts	2.9
Day 5	Cocoa dusted almonds, jicama fries	3.1
Day 6	Dehydrated apples, crunchy chickpeas	3.0
Day 7	Berry & flax oatmeal, crunchy edamame	3.3

Diet Intervention

	Pre-Diet Intervention		Snack	Counseling	
	Baseline dietary fiber (g/1000 kcal)	Baseline diet quality score	Snack compli-	Avg Daily Prebiotic Servings on Own	Avg Daily Prebiotic Servings Consumed
Avg	9.3	67.1	93.9%	3.9	6.5
(min, max)	(6.4, 11.3)	(58.7, 75.7)	(91%, 100%)	(2, 5.5)	(4.4, 8)

Motivational Interviewing

Through open questions, affirmation, reflective and empathetic listening, seek to understand the patient's own motivations. Summarize strategies to empower the patient.


Incentive (Support) Strategies

Provide ready-to-eat PreFED snacks, easy to follow shopping lists and recipes with consistent and personalized follow-up.



Education

Through PreFED handouts, visual aids and interactive discussions, teach concepts and adaptive strategies to increase and maintain prebiotic food intake.



Self-monitoring

Patients observe and record prebiotic food intake to track success, identify challenges and receive feedback on progress.




10 years ago: How influential can dietary habits REALLY be to a patient with cancer? You have the tumor, the treatment, the side effects...



Today: Diet can modulate the gut microbiome, immune function, inflammatory pathways, tumor intrinsic and extrinsic factors...

Chicken vs. egg challenge in toxicity/side effects (inpatient monitoring)


Should we **pre-screen** the microbiome (or diet) of patients



What strategy should we use to **modulate** the microbiome?



Do we need to recommend a specific diet before / after microbiome modulation to **support** or sustain the microbes?



Microbiome Core Facility

Robert Jenq, M.D.
Co-Director

Samuel Shelburne, M.D., Ph.D.
Co-Director

Bionutrition Research Core

Carrie Daniel-MacDougall, PhD, MPH
Karen Basen-Engquist, PhD, MPH
Co-Directors

Platform for Innovative Microbiome and Translational Research

Jennifer Wargo, M.D., MMSc
Director



Nadim Ajami, Ph.D.
Executive Director for Scientific Research

Contact Us →

MD Anderson Bionutrition Research Core

Eating habits are a form of high-dimensional data. We use validated methods and tools to capture dietary data in free-living individuals who eat unique foods and recipes that define their overall habits and nutrient intake.

Human feeding studies parallel preclinical designs. Through our metabolic research kitchen, we conduct precise dietary manipulation in short-term, but intensive human trials to measure biological effects or pharmacokinetics.



Precision nutrition = NIH priority

Thank you to our patients who give their precious time and energy to research - and to the families that support them!

cdaniel@mdanderson.org



Duncan Family Institute

Andrew Sabin Family Fellowship

Moon Shot

Patient Mosaic

Melanoma
Research Alliance

Additional peer-reviewed foundation/philanthropic support for diet studies:

Mark Foundation for Cancer Research

Seerave

Elkins Foundation

Rising Tide